Form 4: Sarepta Therapeutics Director Kathryn Boor Reports Stock Option Grant and RSU Activity

Director Kathryn Boor reports acquisition of stock options and restricted stock units (RSUs) in Sarepta Therapeutics.

Summary

• Kathryn Jean Boor, a director of Sarepta Therapeutics, reported changes in her beneficial ownership of the company's securities.
• On March 1, 2024, Ms. Boor acquired 1,846 shares of common stock through restricted stock units (RSUs) at a price of $0.
• These RSUs will vest in full on March 1, 2025.
• Also on March 1, 2024, Ms. Boor acquired stock options for 3,679 shares of common stock with an exercise price of $128.67, exercisable from March 1, 2025, and expiring on March 1, 2034.
• Following these transactions, Ms. Boor directly owns 3,679 derivative securities and 8,277 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions by a company director. The acquisition of shares and options could be interpreted as a positive sign, but it's not definitively bullish.

Positives

• The acquisition of RSUs and stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment, reflecting insider confidence.

Key Dates